Aushon Biosystems this week said it will collaborate with Peking University Cancer Hospital to develop protein biomarkers for the diagnosis of liver metastases of colorectal cancer.

Under the agreement, Aushon will use its protein biomarker detection platform to develop biomarkers to predict liver metastases of colorectal cancer, as well as stratification biomarkers for radio-chemotherapy patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.